
Chinese pharmaceutical company established on 20 March 2003 in Shanghai as a wholly Taiwan, Hong Kong and Macao invested enterprise, with Wei Jianmin as legal representative and about 59.75 million yuan of registered capital. Operates as an integrated pharmaceutical business built on drug research and manufacturing with agency sales and promotion as a second wing, covering products for neurological, digestive, cardiovascular, psychiatric and immune system disease, and also trades in pharmaceutical wholesale, medical devices and technology import and export. Holds a drug manufacturing licence and national high-tech enterprise status, has invested in seven subsidiaries and owns forty-five patents and twenty-nine registered trademarks.
留下您的评分